HC Wainwright Has Negative Estimate for Celcuity Q3 Earnings

Celcuity, Inc. (NASDAQ:CELC) – Investment analysts at HC Wainwright lowered their Q3 2026 EPS estimates for shares of Celcuity in a research note issued on Wednesday, June 3rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.17) per share for the quarter, down from their prior forecast of ($1.16). HC Wainwright currently has a “Buy” rating and a $145.00 target price on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($3.61) per share. HC Wainwright also issued estimates for Celcuity’s Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($3.90) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at $3.14 EPS, FY2029 earnings at $6.16 EPS and FY2030 earnings at $9.94 EPS.

Several other brokerages also recently weighed in on CELC. Wolfe Research reaffirmed an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a report on Thursday, March 12th. Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a report on Monday, May 4th. Weiss Ratings downgraded shares of Celcuity from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Craig Hallum dropped their target price on shares of Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Citizens Jmp upped their target price on shares of Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a report on Monday, May 4th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $152.09.

Celcuity Trading Up 4.0%

Shares of CELC stock opened at $92.47 on Friday. The company has a market cap of $4.51 billion, a price-to-earnings ratio of -23.71 and a beta of 0.10. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The firm has a fifty day moving average price of $122.45 and a 200-day moving average price of $111.55. Celcuity has a 1 year low of $11.27 and a 1 year high of $151.02.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10.

Insider Activity

In other news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director owned 65,000 shares in the company, valued at $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,000 shares of company stock worth $5,111,950 over the last 90 days. Corporate insiders own 13.33% of the company’s stock.

Institutional Trading of Celcuity

Several hedge funds have recently made changes to their positions in CELC. Avoro Capital Advisors LLC purchased a new stake in shares of Celcuity during the 4th quarter valued at about $310,302,000. NEA Management Company LLC raised its position in shares of Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after buying an additional 1,391,300 shares in the last quarter. State Street Corp raised its position in shares of Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after buying an additional 914,887 shares in the last quarter. Apis Capital Advisors LLC purchased a new stake in shares of Celcuity during the 3rd quarter valued at about $38,334,000. Finally, UBS Group AG grew its holdings in Celcuity by 910.1% during the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after purchasing an additional 769,891 shares during the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Celcuity and reiterated a $145 price target, signaling continued analyst confidence in the company’s long-term outlook. HC Wainwright rating update
• Positive Sentiment: Celcuity said it is expanding the Phase 3 VIKTORIA-2 trial to include endocrine-sensitive breast cancer patients, which could broaden the drug’s potential market and improve the program’s commercial opportunity. VIKTORIA-2 trial expansion
• Positive Sentiment: Several reports highlighted strong Phase 3 breast cancer data for gedatolisib, with commentators describing the results as potentially practice-changing and supportive of a future FDA filing. Strong Phase 3 data article
• Neutral Sentiment: HC Wainwright updated earnings estimates for fiscal 2027, including projected profitability in later quarters, but the revisions were mostly about longer-term modeling rather than an immediate business event. Analyst estimate updates
• Negative Sentiment: Celcuity priced an upsized $500 million convertible senior note offering due 2032, up from an initially planned $400 million, raising dilution and balance-sheet concerns for shareholders. Convertible notes pricing
• Negative Sentiment: Investors also reacted to an ASCO26 trial disappointment, with coverage noting that Celcuity was “punished” after the latest data did not fully meet market expectations. ASCO26 disappointment

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.